These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 37812809)

  • 1. Native SEC and Reversed-Phase LC-MS Reveal Impact of Fab Glycosylation of Anti-SARS-COV-2 Antibodies on Binding to the Receptor Binding Domain.
    Woodall DW; Thomson CA; Dillon TM; McAuley A; Green LB; Foltz IN; Bondarenko PV
    Anal Chem; 2023 Oct; 95(42):15477-15485. PubMed ID: 37812809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antigenic Cross-Reactivity Between SARS-CoV-2 S1-RBD and Its Receptor ACE2.
    Lai YC; Cheng YW; Chao CH; Chang YY; Chen CD; Tsai WJ; Wang S; Lin YS; Chang CP; Chuang WJ; Chen LY; Wang YR; Chang SY; Huang W; Wang JR; Tseng CK; Lin CK; Chuang YC; Yeh TM
    Front Immunol; 2022; 13():868724. PubMed ID: 35603169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
    Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual nature of human ACE2 glycosylation in binding to SARS-CoV-2 spike.
    Mehdipour AR; Hummer G
    Proc Natl Acad Sci U S A; 2021 May; 118(19):. PubMed ID: 33903171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the glycosylation of the receptor binding domain (RBD dimer)-based Covid-19 vaccine (ZF2001) on its humoral immunogenicity and immunoreactivity.
    Wang X; Shi L; Wang Y; Chen J; Yang Z; Liu C; Liu X; Li Y; Zhang C; Sun A; Yan H; Sun H
    Int J Biol Macromol; 2023 Dec; 253(Pt 3):126874. PubMed ID: 37709229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A highly sensitive bead-based flow cytometric competitive binding assay to detect SARS-CoV-2 neutralizing antibody activity.
    Yao X; Zhang Z; Mei Q; Li S; Xing L; Long Y; Zhang D; Wang J; Wang X; Xie B; Yang B; Gao Y; Wu C; Meng Q
    Front Immunol; 2022; 13():1041860. PubMed ID: 36532082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the impact of antibody fragments on aggregation of intact molecules via size exclusion chromatography coupled with native mass spectrometry.
    Xu J; Coughlin JE; Szyjka M; Jabary S; Saluja S; Sosic Z; Chen Y; Xu CF
    MAbs; 2024; 16(1):2334783. PubMed ID: 38536719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The spike-ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies.
    Zhang S; Gao C; Das T; Luo S; Tang H; Yao X; Cho CY; Lv J; Maravillas K; Jones V; Chen X; Huang R
    J Immunol Methods; 2022 Apr; 503():113244. PubMed ID: 35218866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural basis for SARS-CoV-2 Delta variant recognition of ACE2 receptor and broadly neutralizing antibodies.
    Wang Y; Liu C; Zhang C; Wang Y; Hong Q; Xu S; Li Z; Yang Y; Huang Z; Cong Y
    Nat Commun; 2022 Feb; 13(1):871. PubMed ID: 35169135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Computational design and modeling of nanobodies toward SARS-CoV-2 receptor binding domain.
    Yang J; Zhang Z; Yang F; Zhang H; Wu H; Zhu F; Xue W
    Chem Biol Drug Des; 2021 Jul; 98(1):1-18. PubMed ID: 33894099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plant-produced SARS-CoV-2 receptor binding domain (RBD) variants showed differential binding efficiency with anti-spike specific monoclonal antibodies.
    Rattanapisit K; Bulaon CJI; Khorattanakulchai N; Shanmugaraj B; Wangkanont K; Phoolcharoen W
    PLoS One; 2021; 16(8):e0253574. PubMed ID: 34379620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomechanical characterization of SARS-CoV-2 spike RBD and human ACE2 protein-protein interaction.
    Cao W; Dong C; Kim S; Hou D; Tai W; Du L; Im W; Zhang XF
    Biophys J; 2021 Mar; 120(6):1011-1019. PubMed ID: 33607086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A competitive binding-mass spectrometry strategy for high-throughput evaluation of potential critical quality attributes of therapeutic monoclonal antibodies.
    Zhang Z; Yan Y; Wang S; Li N
    MAbs; 2022; 14(1):2133674. PubMed ID: 36224723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Luteolin inhibits spike protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) binding to angiotensin-converting enzyme 2.
    Zhu J; Yan H; Shi M; Zhang M; Lu J; Wang J; Chen L; Wang Y; Li L; Miao L; Zhang H
    Phytother Res; 2023 Aug; 37(8):3508-3521. PubMed ID: 37166054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Combination of Native LC-MS Approaches for the Comprehensive Characterization of the Antibody-Drug Conjugate Trastuzumab Deruxtecan.
    Deslignière E; Diemer H; Erb S; Coliat P; Pivot X; Detappe A; Hernandez-Alba O; Cianférani S
    Front Biosci (Landmark Ed); 2022 Oct; 27(10):290. PubMed ID: 36336868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting SARS-CoV2 Spike Protein Receptor Binding Domain by Therapeutic Antibodies.
    Hussain A; Hasan A; Nejadi Babadaei MM; Bloukh SH; Chowdhury MEH; Sharifi M; Haghighat S; Falahati M
    Biomed Pharmacother; 2020 Oct; 130():110559. PubMed ID: 32768882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure, Dynamics, Receptor Binding, and Antibody Binding of the Fully Glycosylated Full-Length SARS-CoV-2 Spike Protein in a Viral Membrane.
    Choi YK; Cao Y; Frank M; Woo H; Park SJ; Yeom MS; Croll TI; Seok C; Im W
    J Chem Theory Comput; 2021 Apr; 17(4):2479-2487. PubMed ID: 33689337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.
    Deshpande A; Harris BD; Martinez-Sobrido L; Kobie JJ; Walter MR
    Front Immunol; 2021; 12():691715. PubMed ID: 34149735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural and Functional Characterization of SARS-CoV-2 RBD Domains Produced in Mammalian Cells.
    Gstöttner C; Zhang T; Resemann A; Ruben S; Pengelley S; Suckau D; Welsink T; Wuhrer M; Domínguez-Vega E
    Anal Chem; 2021 May; 93(17):6839-6847. PubMed ID: 33871970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.